|
Cellular immune biomarkers to prognosticate for survival to adoptive T-cell therapy in advanced nasopharyngeal cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Tessa Therapeutics |
Leadership - Tessa Therapeutics |
Stock and Other Ownership Interests - Tessa Therapeutics |
Honoraria - Merck Sharp & Dohme |
Consulting or Advisory Role - Tessa Therapeutics |
Patents, Royalties, Other Intellectual Property - Tessa Therapeutics |
Travel, Accommodations, Expenses - Tessa Therapeutics |